title: [Clinicopathologic features of primary thyroid lymphoma].
abstract: OBJECTIVE
  Primary thyroid lymphoma (PTL) is a rare disease. It is likely to be misdiagnosed, and its treatment remains controversy. This study was to investigate clinicopathologic features of PTL, and explore proper treatments.
  
  
  METHODS
  Records of 22 patients with PTL treated in Cancer Hospital, Chinese Academy of Medical Sciences from Jan.1990 to Jan. 2004 were retrospectively analyzed.
  
  
  RESULTS
  Of the 22 patients, 18 were women, 4 were men. The median age is 55 (33-80) years. All patients were B-cell original; according to WHO classification, 16 (72.7%) were diffuse large B-cell lymphoma (DLBCL), and 6 (27.3%) were mucosa associated lymphoid tissue (MALT) lymphoma. Five patients received surgery alone; 7 received radiotherapy after surgery, 6 received chemotherapy after surgery, 4 received chemotherapy and radiotherapy after surgery. With a median follow-up of 42 (1-168) months, 5-year relapse-free survival rate was 34.78%, and 5-year overall survival rate was 37.36%.
  
  
  CONCLUSIONS
  PTL typically occurs in women. The majority of PTL is B-cell original; DLBCL, and MALT lymphoma were the most common histological subtypes. Patients with PTL of stage IE or IIE should be treated with surgery-based combined modality.
authors.affiliation: Department of Medical Oncology, Cancer Institute/Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100-021, P.R. China.
authors.forename: Sheng-Yu
authors.initials: SY
authors.lastname: Zhou
authors.forename: Ding-Zhi
authors.initials: DZ
authors.lastname: Huang
authors.forename: Yuan-Kai
authors.initials: YK
authors.lastname: Shi
authors.forename: Xiao-Hui
authors.initials: XH
authors.lastname: He
authors.forename: Yao-Huang
authors.initials: YH
authors.lastname: Wu
authors.forename: Ye-Xiong
authors.initials: YX
authors.lastname: Li
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008197:Lymph Node Excision; D008207:Lymphatic Metastasis; D018442:Lymphoma, B-Cell, Marginal Zone / Q000473:pathology / Q000628:therapy*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000473:pathology / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000008:administration & dosage; D018714:Radiotherapy, Adjuvant; D012189:Retrospective Studies; D012737:Sex Factors; D013964:Thyroid Neoplasms / Q000473:pathology / Q000628:therapy*; D013965:Thyroidectomy / Q000379:methods; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone